Gamma-lactams-A novel scaffold for highly potent and selective α7 nicotinic acetylcholine receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 5, 2009, Pages 1287-1291

  Enz, Albert ^a   Feuerbach, Dominik ^a   Frederiksen, Mathias U ^a   Gentsch, Conrad ^a   Hurth, Konstanze ^a   Müller, Werner ^a   Nozulak, Joachim ^a   Roy, Bernard L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

7; Lactams; nAChR; Nicotinic

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; AR R17779; AR R1779; GAMMA LACTAM DERIVATIVE; JN 403; N (1 AZABICYCLO[3.2.1]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MOUSE; NONHUMAN;

ANIMALS; BINDING SITES; BRAIN; HUMANS; LACTAMS; MICE; NICOTINIC AGONISTS; PROTEIN BINDING; RABBITS; RECEPTORS, NICOTINIC;

MUS;

EID: 60749100712     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.073     Document Type: Article

References (18)

1. For recent reviews, see:. Cincotta S.L., Yorek M.S., Moschak T.M., Lewis S.R., and Rodefer J.S. Curr. Opin. Invest. Drugs 9 (2008) 47
2. Mazurov A., Hauser T., and Miller C.H. Curr. Med. Chem. 13 (2006) 1567
3. Jensen A.A., Frølund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 48 (2005) 4705
4. Dunbar G.C., Inglis F., Kuchibhatla R., Sharma T., Tomlinson M., and Wamsley J. J. Psychopharmacol. 21 (2004) 171
5. Chiamulera C., and Fumagalli G. Cent. Nerv. Syst. Agents Med. Chem. 7 (2007) 269
6. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., Al Abed Y., Wang H., Metz C., Miller E.J., Tracey K.J., and Ulloa L. Nat. Med. 10 (2004) 1216
7. Feuerbach D., Nozulak J., Lingenhoehl K., McAllister K., and Hoyer D. Neurosci. Lett. 416 (2007) 61
8. Acker B.A., Jacobsen E.J., Rogers B.N., Wishka D.G., Reitz S.C., Piotrowski D.W., Myers J.K., Wolfe M.L., Groppi V.E., Thornburgh B.A., Tinholt P.M., Walters R.R., Olson B.A., Fitzgerald L., Staton B.A., Raub T.J., Krause M., Li K.S., Hoffmann W.E., Hajos M., Hurst R.S., and Walker D.P. Bioorg. Med. Chem. Lett. 18 (2008) 3611
9. Sheridan R.P., Nilakantan R., Dixon J.S., and Venkataraghavan R. J. Med. Chem. 29 (1986) 899
10. 50 values 6.34 versus 6.01, respectively. The depicted (S,S)-configuration was later confirmed to be the eutomer by enantioselective synthesis of 20 (vide infra Scheme 2). All stereochemistry is therefore given as the (S,S)-configuration.
11. Feuerbach D., Lingenhöhl K., Dobbins P., Mosbacher J., Corbett N., Nozulak J., and Hoyer D. Neuropharmacology 48 (2005) 215
12. Michelmore S., Croskery K., Nozulak J., Hoyer D., Longato R., Weber A., Bouhelal R., and Feuerbach D. Naunyn-Schmiedeberg's. Arch. Pharmacol 366 (2002) 235
13. Feuerbach D., Lingenhoehl K., Olpe H.-R., Vassout A., Gentsch C., Chaperon F., Nozulak J., Enz A., Bilbe G., McAllister K., and Hoyer D. J. Neuropharm. 56 (2009) 254
14. Miyaura N., and Suzuki A. Chem. Rev. 95 (1995) 2457
15. Tohda Y., Sonogashira K., and Hagihara N. Synthesis (1977) 777
16. Chiral separation performed on Chiralpak OD or AH columns.
17. Dembélé Y.A., Belaud C., Hitchcock P., and Villiéras J. Tetrahedron: Asymm. 3 (1992) 351
18. Yamamoto Y., and Ito W. Tetrahedron 44 (1988) 5415